Literature DB >> 2953616

Shared idiotopes between anti-class II monoclonal antibodies and major histocompatibility complex recognition site of T cells.

M Tsuji, J Yagi, R Abe, Y Asano, T Tada.   

Abstract

We have raised a number of monoclonal antibodies (mAb) against idiotopes (Id) on monoclonal anti-murine class II (anti-Ak or Ek) antibodies. Two anti-Id mAb among 31 were found to cross-react with some T cells but not with macrophages and B cells of H-2k animals. They were able to block syngeneic mixed lymphocyte reaction (SMLR) and antigen-induced major histocompatibility complex (MHC)-restricted T cell proliferation of H-2k but not of other haplotypes. These results indicated that antibodies were recognizing Id associated with the MHC restriction site of T cells. The injection of these anti-Id mAb into H-2k mice resulted in the stimulation of self-class II-reactive T cell clones as determined by SMLR. They were also able to stimulate in non-H-2k strains to prime H-2k alloreactive T cell clones. Some animals developed anti-class II (anti-Iak) antibodies by the injection of anti-Id. These results indicated that certain anti-Id (anti-anti-class II) antibodies cross-reacted with T cell receptors which carried class II restriction specificity and were involved in allorecognition. These antibodies were found to have an ability to alter the T cell repertoire in vivo by stimulating such MHC-restricted clones.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2953616     DOI: 10.1002/eji.1830170515

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  2 in total

1.  Mechanism of MHC class II restriction in the interaction between specific suppressor and responder T cells in a proliferative response: Ia interaction with a putative anti-self receptor, expressed on pre-activated responder cells.

Authors:  M B Zaitseva; B D Brondz
Journal:  Immunology       Date:  1990-07       Impact factor: 7.397

2.  CD4+ cytolytic T cell clone confers protection against murine malaria.

Authors:  M Tsuji; P Romero; R S Nussenzweig; F Zavala
Journal:  J Exp Med       Date:  1990-11-01       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.